GE HealthCare Technologies Inc. (GEHC) rises on deep earnings beat
GE HealthCare Technologies Inc. (GEHC) rises after a broad Q3 beat that went beyond the headline. This deep-dive covers margin expansion, segment strength, cash flow gains, and the company’s raised full-year outlook, showing how volume, pricing, and execution drove the move.
GE HealthCare Technologies Inc. (GEHC) delivered a strong third quarter, beating estimates on both adjusted EPS and revenue while raising its full-year outlook. The quarter showed improving execution across the business, with margin expansion, higher free cash flow, and solid growth in Pharmaceutical Diagnostics and Patient Care Solutions supporting the stock’s sharp gain. For investors, the report signals that GEHC’s turnaround is gaining traction and that management sees continued momentum into 2026.
GE HealthCare Technologies Inc. (GEHC) rises on Q3 earnings
GE HealthCare Technologies Inc. (GEHC) rises 6.36% after a strong third-quarter 2026 beat on adjusted EPS and revenue. The company also raised its full-year outlook, while higher volume, pricing actions, and better execution lifted margins across the business.
GEHC earnings came in at adjusted EPS of $1.34, ahead of the $1.20 estimate, while revenue reached $5.51B against a $5.35B consensus. Shares traded at $75.63 during the regular session, with volume of 6.6M shares versus a 3.56M average.
Key Takeaways
Adjusted EPS of $1.34 beat the $1.20 estimate and rose 25.1% year over year.
Revenue of $5.51B beat the $5.35B estimate, with organic growth of 6.2% across all segments.
Pharmaceutical Diagnostics delivered the strongest segment growth at 13.8% organically, while Patient Care Solutions improved sharply after earlier supply problems.
Adjusted EBIT margin expanded 180 basis points to 16.6%, and free cash flow rose $310M year over year to $793M.
GE HealthCare raised 2026 guidance to approximately 4% organic revenue growth, 15.5% to 15.7% adjusted EBIT margin, $4.95 to $5.05 adjusted EPS, and more than $1.6B of free cash flow.
Analyst sentiment remains constructive, with 11 Buy ratings, 8 Hold ratings, and no Sell ratings in the current consensus.
GEHC Financial Performance: A Beat Built on Volume and Execution
The GE HealthCare Technologies Inc. earnings analysis starts with a clean top-line and bottom-line beat. Revenue reached $5.51B, up from $5.29B in the second quarter and $5.14B in the year-ago quarter. Organic revenue growth reached 6.2%, while product revenue grew 6.7% and service revenue grew 8.1% on a reported basis.
Adjusted EPS also continued its upward trend. GEHC reported $1.34 in the third quarter, compared with $1.13 in the second quarter and $0.99 in the first quarter. The company beat estimates in the third quarter after a $1.13 versus $1.04 beat in the second quarter. It missed the $1.04 estimate in the first quarter, so the latest result marks a clear improvement in earnings consistency.
Profitability was the central financial story. Adjusted EBIT margin reached 16.6%, an expansion of 180 basis points from the prior year. Volume supported the gain, while pricing and cost mitigation actions added further support. Lower tariff expense also helped. However, inflation in memory chips and higher oil prices continued to pressure the cost base.
Cash flow added another layer of strength. Free cash flow reached $793M, up $310M year over year. Management attributed the improvement to stronger operating profit, collection timing, and lower net tariff impact. GE HealthCare also raised its cash dividend by 14%, which adds to shareholder returns while the company continues to invest in product development and supply-chain capacity.
Advanced Imaging Solutions produced 4.5% organic revenue growth. CT, cardiovascular, interventional solutions, and surgical innovations drove the performance. Segment EBIT margin expanded 130 basis points through volume, pricing, and lower tariff expense, although inflation offset part of the gain.
Pharmaceutical Diagnostics was the standout segment. Organic revenue growth reached 13.8%, supported by contrast media and radiopharmaceuticals. Segment EBIT margin rose 50 basis points to 29.9%. Volume and pricing led the expansion, while planned investment in new products reduced part of the benefit.
Patient Care Solutions delivered 8.8% organic revenue growth and a 480-basis-point year-over-year margin expansion. Better product fulfillment, monitoring solutions, and maternal and infant care drove the rebound. The segment also converted more backlog into revenue after earlier supplier and factory problems. The comparison includes a $45M revenue benefit from a product-hold release in the fourth quarter of 2025, which creates a tougher comparison ahead.
Orders grew 4% organically, and book-to-bill reached 1.03x. Backlog ended the quarter at $23.7B, up $2.5B or 12% year over year. That backlog provides a meaningful operating cushion, although the slower order growth and lower book-to-bill ratio explain why analysts pressed management on demand timing.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
GEHC shares reacted quickly to the beat-and-raise result. Early trading lifted the stock about 5.7% to $75.17 from a prior close of $71.11. By 3:30 p.m. ET, shares stood at $75.63, up 6.36% during the regular session.
Trading activity also confirmed strong interest. Volume reached 6.6M shares, compared with a 3.56M average. The combination of a sizable price move and heavier trading shows that investors treated the quarter as more than a routine estimate beat.
The current analyst consensus is Buy, with 11 Buy ratings and 8 Holds. No Sell or Strong Sell ratings appear in the consensus. The positive view reflects the earnings beat, the higher full-year outlook, record backlog, and expanding margins.
Still, the analyst response was not blindly bullish. Questions focused on the 1.03x book-to-bill ratio, capital spending, China, tariffs, and the durability of margin expansion in 2027. Those topics frame the difference between a strong quarter and a durable operating inflection.
Management Commentary: Strategy, Demand, and Guidance
CEO Peter Arduini presented the quarter as proof that GE HealthCare's operating system is improving. He pointed to standard work, daily management, and commercial simplification as practical tools that helped Patient Care Solutions fix fulfillment issues. In plain English, the company is trying to make better execution repeatable rather than dependent on a few strong quarters.
"Heartbeat is strengthening how we run the company. And helping our teams deliver on commercial and operational simplification." - Peter J. Arduini, CEO, Earnings Call
Arduini also emphasized the longer-term growth case. GE HealthCare received CE marking for its PhotoNova Spectra photon-counting CT system and advanced its Starguide GX SPECT CT system toward wider commercialization. The company expanded ultrasound offerings in cardiovascular, women's health, and general imaging. It also plans to acquire SoFi Bioscience to strengthen final-mile radiopharmaceutical distribution and add access to the FAPI 74 cancer tracer.
CFO William Grogan focused on the numbers. He highlighted profitable growth, margin expansion, free cash flow, and the benefit from pricing and cost actions. His outlook gives investors a clear financial framework for the rest of 2026.
"Our continued execution gives us increased confidence in our outlook." - William K. Grogan, CFO, Earnings Call
Grogan raised full-year 2026 guidance across several measures. Organic revenue growth now stands at approximately 4%. Adjusted EBIT margin is expected at 15.5% to 15.7%, adjusted EPS at $4.95 to $5.05, and free cash flow above $1.6B. The company also expects a 20% to 21% adjusted effective tax rate and a foreign-exchange revenue tailwind of approximately 75 basis points.
Bank of America's Travis Steed challenged the demand picture behind the quarter. He pointed out that book-to-bill was 1.03x, the lowest level since the first quarter of 2024, and asked whether capital spending was weakening. The pushback mattered because backlog growth can hide a slowdown in fresh orders for several quarters.
"1.03x was the lowest since Q1 2024." - Travis Steed, Bank of America, Earnings Call
"Our orders book looks a little bit better than we actually had in Q3." - Peter J. Arduini, CEO, Earnings Call
Arduini defended the demand outlook by saying imaging remains a high priority in customer capital budgets. He also said GE HealthCare had no direct evidence of a procedure slowdown. His answer framed the weaker book-to-bill as order timing rather than a broad reduction in demand.
Evercore ISI's Vijay Kumar pressed management on whether China had reached a bottom. GE HealthCare reported quarterly improvement in China, but Arduini separated reported growth from underlying demand. He said quarterly growth reached 7%, while most of that increase still came from foreign exchange.
"China is definitely recovering, but there is still lots of wood to chop." - Peter J. Arduini, CEO, Earnings Call
That response was constructive but restrained. China is improving, yet the company's own description rules out a full recovery narrative. Analysts also pressed on tariffs and the durability of margin gains. Management said third-quarter tariff expense fell through mitigation actions, lower rates, and roughly $4M of IEEPA tariff refunds. Section 232 remained the largest tariff uncertainty for the 2027 planning cycle.
Bottom Line
GEHC earnings delivered the combination investors reward: a revenue and EPS beat, wider margins, stronger cash flow, and higher guidance. The next phase of the story rests on turning backlog into orders and revenue while sustaining the execution gains in Patient Care Solutions and the high growth in Pharmaceutical Diagnostics.
For now, GE HealthCare enters the next quarter with a $23.7B backlog, a Buy consensus, and a clearer path toward its 2026 targets. China and tariffs remain real variables, but the latest results give the company operating momentum.
GE HealthCare Technologies Inc. (GEHC) rose 6.36% after reporting adjusted EPS of $1.34 versus the $1.20 estimate and revenue of $5.51B versus the $5.35B consensus. Investors also reacted positively to higher full-year guidance, margin expansion, and stronger free cash flow.
+Did GE HealthCare beat on both earnings and revenue in Q3?
Yes, GE HealthCare Technologies Inc. (GEHC) beat on both metrics in the third quarter. Adjusted EPS came in at $1.34, above the $1.20 estimate, and revenue reached $5.51B, topping the $5.35B consensus.
+What did GE HealthCare raise its 2026 guidance to?
GE HealthCare raised 2026 guidance to about 4% organic revenue growth, a 15.5% to 15.7% adjusted EBIT margin, and adjusted EPS of $4.95 to $5.05. The company also expects more than $1.6B in free cash flow.
+Which GE HealthCare segment grew the fastest in Q3?
Pharmaceutical Diagnostics was the fastest-growing segment, with 13.8% organic revenue growth. Patient Care Solutions also improved sharply, while Advanced Imaging Solutions posted 4.5% organic growth.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on GEHC?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
